Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VB10.16 + atezolizumab
- Development stage
- Unknown
- Lead developer
- Nykode Therapeutics
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intramuscular, Intravenous
01
Overview
VB10.16 + atezolizumab is a combination regimen consisting of VB10.16, a DNA-based therapeutic HPV16-specific cancer vaccine, and atezolizumab, a monoclonal antibody immune checkpoint inhibitor targeting programmed death-ligand 1 (PD-L1). VB10.16 encodes HPV16 E6/E7 oncoproteins fused to CCL3L1 for antigen-presenting cell targeting, aiming to elicit strong HPV16-specific T-cell responses. Combined with atezolizumab, which blocks PD-L1 to boost antitumor immunity, this regimen is studied for synergistic activity in persistent, recurrent, or metastatic HPV16-positive cervical cancer[1][2][5].
- Other names
- VB10.16 + Tecentriq
02
Targets
HPV16 E6 oncoproteinHPV16 E7 (Human papillomavirus 16 E7 protein)CCR5 (C-C chemokine receptor type 5)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on VB10.16 + atezolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VB10.16 + atezolizumab.